Sapablursen was granted Fast Track designation and orphan drug designation in 2024 by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, ...

Sapablursen is currently being evaluated in a Phase II study (NCT05143957) in patients with PV, a rare type of blood cancer. A total of 50 patients will be subcutaneously administered with one or ...

Sapablursen is currently being evaluated in adults living with PV in the fully enrolled Phase 2 IMPRSSION study. Also Read: Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Sapablursen is currently in a phase 2 trial for polycythemia vera (PV), a rare blood condition characterized by the overproduction of red blood cells.

The CEO went on to discuss sapablursen, a drug candidate he called “more interesting.” In 2019, Ionis moved the prospect into a phase 2 trial in non-transfusion-dependent beta thalassemia ...

CARLSBAD, Calif. & OSAKA, Japan, March 11, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a ...

Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. See how Matt Maley is positioning for post-Fed volatility and momentum—live this Sunday, ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global ...